- In March 2024, ViiV Healthcare, a specialist HIV company majority-owned by GSK, received expanded FDA approval for its long-acting injectable regimen Cabenuva (cabotegravir and rilpivirine) for broader use in adolescent patients aged 12 and older. This development marks a significant step forward in making simplified, low-frequency dosing options accessible to younger populations, enhancing adherence and reducing stigma, particularly in high-burden settings
- In February 2024, Gilead Sciences Inc. initiated Phase III trials for a novel once-weekly oral antiretroviral therapy combining lenacapavir with investigational agents, targeting better adherence and reduced resistance. The advancement reinforces Gilead's leadership in developing long-acting HIV treatments and represents a shift toward more patient-centric regimens
- In January 2024, the Joint United Nations Programme on HIV/AIDS (UNAIDS) launched a multi-country initiative focused on eliminating vertical transmission of HIV in sub-Saharan Africa by 2030. The program, supported by new treatment guidelines and ART scale-up strategies, emphasizes the importance of early maternal ART intervention and continuous treatment access, signaling intensified global commitment to eradicating AIDS among children
- In December 2023, Cipla Limited partnered with the Clinton Health Access Initiative (CHAI) to expand the distribution of affordable, high-quality antiretroviral drugs in low-income countries. This collaboration aims to improve accessibility by strengthening supply chains and facilitating generic ART production under voluntary licensing agreements, particularly in Asia and Africa
- In November 2023, Theratechnologies Inc. announced positive trial results for its investigational therapy TH1902, a peptide-drug conjugate targeting HIV-infected cells with enhanced precision. This innovative approach offers potential to overcome traditional ART limitations, reduce viral reservoirs, and address long-term treatment goals. The progress reflects ongoing innovation in next-generation AIDS therapies aimed at improving outcomes and quality of life
